​

Monopar Therapeutics (MNPR) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

MNPR Stock Forecast

Monopar Therapeutics (MNPR) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $29.50, with a high of $37.00 and a low of $22.00. This represents a -22.41% decline from the last price of $38.02.

- $8 $16 $24 $32 $40 High: $37 Avg: $29.5 Low: $22 Last Closed Price: $38.02

MNPR Stock Rating

Monopar Therapeutics stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (71.43%), 2 Hold (28.57%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 2 5 Strong Sell Sell Hold Buy Strong Buy

MNPR Price Target Upside V Benchmarks

TypeNameUpside
StockMonopar Therapeutics-22.41%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$29.50
Last Closing Price$38.02$38.02$38.02
Upside/Downside---22.41%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2522---4
Mar, 2522---4
Feb, 2522---4
Jan, 2522---4
Dec, 2412---3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 19, 2024Justin WalshUBS$37.00$19.0194.63%-2.68%
Nov 11, 2024Sean LeeH.C. Wainwright$22.00$15.8139.15%-42.14%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 10, 2025Piper SandlerOverweightinitialise
Oct 11, 2024Rodman & RenshawBuyinitialise
Aug 12, 2024H.C. WainwrightBuyBuyhold
Jan 28, 2021Roth CapitalBuyinitialise

Financial Forecast

EPS Forecast

$-450 $-350 $-250 $-150 $-50 $50 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.58$-411.23----
Avg Forecast$-3.30$-1.29$-2.38$-1.48$0.53$1.86
High Forecast$-3.30$-1.26$-1.27$0.70$3.17$1.86
Low Forecast$-3.30$-1.31$-3.49$-3.95$-3.69$1.86
Surprise %-82.42%31778.29%----

Revenue Forecast

$10M $23M $36M $49M $62M $75M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$14.52M$42.50M$70.72M
High Forecast---$14.52M$42.50M$70.72M
Low Forecast---$14.52M$42.50M$70.72M
Surprise %------

Net Income Forecast

$-20B $-15B $-10B $-5B $0 $5B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-8.40M$-15.59B----
Avg Forecast$-47.89M$-18.69M$-34.53M$-15.84M$-8.53M$26.99M
High Forecast$-47.89M$-18.35M$-18.42M$10.16M$46.00M$26.99M
Low Forecast$-47.89M$-19.03M$-50.65M$-57.32M$-53.55M$26.99M
Surprise %-82.45%83291.11%----

MNPR Forecast FAQ

Is Monopar Therapeutics stock a buy?

Monopar Therapeutics stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Monopar Therapeutics is a favorable investment for most analysts.

What is Monopar Therapeutics's price target?

Monopar Therapeutics's price target, set by 7 Wall Street analysts, averages $29.5 over the next 12 months. The price target range spans from $22 at the low end to $37 at the high end, suggesting a potential -22.41% change from the previous closing price of $38.02.

How does Monopar Therapeutics stock forecast compare to its benchmarks?

Monopar Therapeutics's stock forecast shows a -22.41% downside, underperforming the average forecast for the healthcare stocks sector (33.91%) and underperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Monopar Therapeutics over the past three months?

  • April 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Monopar Therapeutics’s EPS forecast?

Monopar Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.38, marking a -99.42% decrease from the reported $-411 in 2024. Estimates for the following years are $-1.48 in 2026, $0.53 in 2027, and $1.86 in 2028.

What is Monopar Therapeutics’s revenue forecast?

Monopar Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $14.52M, followed by $42.5M for 2027, and $70.72M for 2028.

What is Monopar Therapeutics’s net income forecast?

Monopar Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-34.533M, representing a -99.78% decrease from the reported $-15.586B in 2024. Projections indicate $-15.836M in 2026, $-8.525M in 2027, and $26.99M in 2028.